EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial

Frank W G Leebeek iD, Flora Peyvandi iD, Andreas Tiede iD, Giancarlo Castaman iD, Miguel Escobar iD, Michael Wang, Bulent Zülfikar iD, Sophie Susen iD, Wolfgang Miesbach iD, Scarlett Wang, Yi Wang iD, Jingmei Zhang und 1 weitere

European Journal of Haematology · 2023

DOI: 10.1111/ejh.13949 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Frank W G Leebeek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: von Willebrand Diseases, von Willebrand Disease, Type 3. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Baxalta Innovations GmbH, a Takeda company, Vienna, Austria, Baxalta US Inc., a Takeda company, Lexington, Massachusetts.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To describe efficacy/safety of recombinant von Willebrand factor (rVWF) prophylaxis in patients with type 3 von Willebrand disease (VWD).

Methods

This post hoc analysis of a phase 3 open‐label trial provides a more detailed analysis of adults with type 3 VWD, categorized based on prior treatment at screening: “Prior On‐Demand (OD)” (OD VWF; ≥3 documented spontaneous bleeding events [BEs] requiring VWF in previous 12 months) or “Switch” (plasma‐derived [pd] VWF prophylaxis for ≥12 months). Annualized bleeding rates (ABRs) were evaluated during 12 months of rVWF prophylaxis versus historical data from medical records.

Results

In the Prior OD group ( n = 10), mean spontaneous ABR (sABR) for treated BEs was reduced by 91.6% (ratio, 0.08; 95% CI, 0.02–0.45) versus mean historical sABR. In the Switch group ( n = 8), mean sABR for treated BEs was reduced by 47% (ratio, 0.53; 95% CI, 0.08–3.62). One non‐serious adverse event (AE) was considered possibly related to rVWF. No treatment‐related, fatal, or life‐threatening serious AEs were reported, and no patient developed VWF inhibitors. Conclusions rVWF prophylaxis reduced sABR in type 3 VWD patients previously treated with OD VWF therapy, and maintained a similar level of hemostatic control in those switching from pdVWF prophylaxis to rVWF prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Diseasesvon Willebrand Disease, Type 3AdultHumansvon Willebrand FactorRecombinant ProteinsHemorrhageAlkanesulfonic Acids

Stichwörter der Autor:innen

bleedingprophylaxisrecombinant von Willebrand factorvon Willebrand disease type 3

Substanzen

von Willebrand FactorRecombinant ProteinsBESAlkanesulfonic Acids

Autor:innen und Institutionen

  • Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Department of Hematology, Hemostasis, Hannover Medical School, Oncology and Stem Cell Transplantation, Hannover, Germany.
  • Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.
  • University of Texas Health Science Center at Houston, Houston, Texas, USA.

ORCID-Profile: Frank W G Leebeek, Flora Peyvandi, Andreas Tiede, Giancarlo Castaman, Miguel Escobar, Bulent Zülfikar, Sophie Susen, Wolfgang Miesbach, Yi Wang

Förderung

  • Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
  • Baxalta US Inc., a Takeda company, Lexington, Massachusetts

Zitieren

APA

Leebeek, F. W. G., Peyvandi, F., Tiede, A., Castaman, G., Escobar, M., Wang, M., Zülfikar, B., Susen, S., Miesbach, W., Wang, S., Wang, Y., Zhang, J., & Özen, G. (2023). Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial. European Journal of Haematology. https://doi.org/10.1111/ejh.13949

Vancouver

Leebeek FWG, Peyvandi F, Tiede A, Castaman G, Escobar M, Wang M, et al. Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial. European Journal of Haematology. 2023. doi:10.1111/ejh.13949

BibTeX
@article{Leebeek2023,
  author = {Leebeek, Frank W G and Peyvandi, Flora and Tiede, Andreas and Castaman, Giancarlo and Escobar, Miguel and Wang, Michael and Zülfikar, Bulent and Susen, Sophie and Miesbach, Wolfgang and Wang, Scarlett and Wang, Yi and Zhang, Jingmei and Özen, Gülden},
  title = {Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.13949}
}
Kostenlos starten →